Literature DB >> 8644863

Interleukin-8 in Hodgkin's disease. Preferential expression by reactive cells and association with neutrophil density.

H D Foss1, H Herbst, S Gottstein, G Demel, I Araujó, H Stein.   

Abstract

Hodgkin's disease (HD) shows rare neoplastic Hodgkin and Reed-Sternberg cells embedded in an abundant reactive infiltrate containing, among other cell types, neutrophilic granulocytes. Interleukin (IL)-8 is chemotactic for neutrophils. The expression of IL-8 was tested by in situ hybridization with 35S-labeled IL-8-specific RNA probes on 38 cases of HD. Reactive lesions, non-Hodgkin's lymphomas of B and T phenotype, and Langerhans cell histiocytosis served as controls. IL-8 expression was observed in Hodgkin and Reed-Sternberg cells in 3 of 33 cases of classical HD and in reactive cells in 20 of 33 HD cases as evidenced by combined isotopic in situ hybridization and immunohistology for the demonstration of cell-type-characteristic antigens or enzyme histochemistry for chloroacetate esterase. IL-8-positive cells were more numerous in cases of nodular sclerosing HD as compared with the mixed cellularity histotype (P = 0.01). The number of IL-8-positive cells and the density of neutrophils were positively correlated (P < 0. 01). In 5 cases of lymphocyte-predominant HD, IL-8 expression was not displayed. Non-Hodgkin's lymphoma cases contained IL-8 transcripts only in 1 of 23 cases in sparse reactive cells. In 4 of 7 cases of Langerhans cell histiocytosis, IL-8-specific signals were displayed in S100-negative cells. In conclusion, IL-8 expression in HD is largely confined to reactive cells and associated with infiltration by neutrophils. Elaboration of other cytokines by Hodgkin and Reed-Sternberg cells and reactive cells may explain the frequent expression of this cytokine in HD, particularly in the nodular sclerosing type.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8644863      PMCID: PMC1861543     

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  35 in total

1.  Production and characterization of monoclonal antibodies against the novel neutrophil activating peptide NAP/IL-8.

Authors:  M Sticherling; J M Schröder; E Christophers
Journal:  J Immunol       Date:  1989-09-01       Impact factor: 5.422

2.  Specificity of riboprobes for intracellular RNA in hybridization histochemistry.

Authors:  D J Williamson
Journal:  J Histochem Cytochem       Date:  1988-07       Impact factor: 2.479

3.  In situ hybridization for procollagen types I, III and IV mRNA in normal and fibrotic rat liver: evidence for predominant expression in nonparenchymal liver cells.

Authors:  S Milani; H Herbst; D Schuppan; E G Hahn; H Stein
Journal:  Hepatology       Date:  1989-07       Impact factor: 17.425

4.  Immunoenzymatic labeling of monoclonal antibodies using immune complexes of alkaline phosphatase and monoclonal anti-alkaline phosphatase (APAAP complexes).

Authors:  J L Cordell; B Falini; W N Erber; A K Ghosh; Z Abdulaziz; S MacDonald; K A Pulford; H Stein; D Y Mason
Journal:  J Histochem Cytochem       Date:  1984-02       Impact factor: 2.479

Review 5.  Neutrophil-activating peptide-1/interleukin 8, a novel cytokine that activates neutrophils.

Authors:  M Baggiolini; A Walz; S L Kunkel
Journal:  J Clin Invest       Date:  1989-10       Impact factor: 14.808

Review 6.  Tumour necrosis factor: a cytokine with multiple biological activities.

Authors:  G Semenzato
Journal:  Br J Cancer       Date:  1990-03       Impact factor: 7.640

7.  Interleukin 4 is at 5q31 and interleukin 6 is at 7p15.

Authors:  G R Sutherland; E Baker; D F Callen; V J Hyland; G Wong; S Clark; S S Jones; L K Eglinton; M F Shannon; A F Lopez
Journal:  Hum Genet       Date:  1988-08       Impact factor: 4.132

8.  The neutrophil-activating protein (NAP-1) is also chemotactic for T lymphocytes.

Authors:  C G Larsen; A O Anderson; E Appella; J J Oppenheim; K Matsushima
Journal:  Science       Date:  1989-03-17       Impact factor: 47.728

9.  Molecular cloning of a human monocyte-derived neutrophil chemotactic factor (MDNCF) and the induction of MDNCF mRNA by interleukin 1 and tumor necrosis factor.

Authors:  K Matsushima; K Morishita; T Yoshimura; S Lavu; Y Kobayashi; W Lew; E Appella; H F Kung; E J Leonard; J J Oppenheim
Journal:  J Exp Med       Date:  1988-06-01       Impact factor: 14.307

10.  Inhibition of interleukin 8 attenuates angiogenesis in bronchogenic carcinoma.

Authors:  D R Smith; P J Polverini; S L Kunkel; M B Orringer; R I Whyte; M D Burdick; C A Wilke; R M Strieter
Journal:  J Exp Med       Date:  1994-05-01       Impact factor: 14.307

View more
  4 in total

1.  The monocyte chemotactic protein a (MCP-1) and interleukin 8 (IL-8) in Hodgkin's disease and in solid tumours.

Authors:  M G Luciani; A Stoppacciaro; G Peri; A Mantovani; L P Ruco
Journal:  Mol Pathol       Date:  1998-10

2.  Discriminant analysis involving serum cytokine levels and prediction of the response to therapy of patients with Hodgkin lymphoma.

Authors:  Maria Kowalska; Joanna Tajer; Magdalena Chechlinska; Malgorzata Fuksiewicz; Beata Kotowicz; Małgorzata Syczewska; Jan Walewski; Janina Kaminska
Journal:  Tumour Biol       Date:  2012-06-08

3.  Primary central nervous system lymphoma secretes monocyte chemoattractant protein 1.

Authors:  Ryuhei Kitai; Kazuyo Ishisaka; Kazufumi Sato; Takahiro Sakuma; Takahiro Yamauchi; Yoshiaki Imamura; Hideki Matsumoto; Toshihiko Kubota
Journal:  Med Mol Morphol       Date:  2007-03-29       Impact factor: 2.309

4.  Defining the Inflammatory Plasma Proteome in Pediatric Hodgkin Lymphoma.

Authors:  Jennifer E Agrusa; Brooks P Scull; Harshal A Abhyankar; Howard Lin; Nmazuo W Ozuah; Rikhia Chakraborty; Olive S Eckstein; Nitya Gulati; Elmoataz Abdel Fattah; Nader K El-Mallawany; Rayne H Rouce; ZoAnn E Dreyer; Julienne Brackett; Judith F Margolin; Joseph Lubega; Terzah M Horton; Catherine M Bollard; M Monica Gramatges; Kala Y Kamdar; Kenneth L McClain; Tsz-Kwong Man; Carl E Allen
Journal:  Cancers (Basel)       Date:  2020-12-02       Impact factor: 6.639

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.